Table 5
From the following article
India's health biotech sector at a crossroads
Sarah E Frew, Rahim Rezaie, Stephen M Sammut, Monali Ray, Abdallah S Daar & Peter A Singer
Nature Biotechnology 25, 403 - 417 (2007)
doi:10.1038/nbt0407-403
Table 5. Collaborations/partnerships between companies interviewed and foreign entities
| Company name | Alliances and their objectives |
|---|---|
| Avestha Gengraine Technologies | Collaboration with bioMerieux (Marcy L'Etoile, France) for co-development of diagnostic chips for tuberculosis. Working with Sequenom (San Diego) for validation of genetic markers for breast cancer, lung cancer and diabetes. Co-development of medicinal plants with Nestle Nutrition (Vevey, Switzerland) and discovery of plant based nutraceuticals for osteoporosis with the Center for Clinical and Basic Research (Ballerup, Denmark). Collaboration with Imperial College (London), research into the genetic analysis of systemic lupus erythematosus (SLE). Collaborative research with AstraZeneca (London) on Mycobacterium tuberculosis (the causative agent of TB). Agreement with TNO Quality of Life (Leiden, The Netherlands) to develop therapeutics targeted at obesity |
| Bharat Biotech International (BBIL) | Contract manufacturing with Wyeth (Madison, NJ USA) for HibTITER. This also let BBIL become the first Indian Bio-Pharma company to be approved by the Korean FDA. Contract manufacturing and marketing for the investigational Japanese encephalitis vaccine with Acambis (Cambridge, UK). Rotavirus, typhoid and rabies vaccine clones were developed with help from the US National Institutes of Health (Bethesda, MD US). Strategic alliance with Novavax (Rockville, MD, US) to pursue the rapid development of pandemic influenza vaccine for India and other Association of Southeast Asian Nations (ASEAN) markets. |
| Bharat Serums & Vaccines | Marketing and distribution of drug portfolio with two US-based companies. Co-developed a novel formulation for an anti-fungal (amphotericin) with a company in the US. Some molecular characterization work through Northern Lipids (Vancouver) |
| Biocon | Co-development of human antibodies with Vaccinex (Rochester, NY US). Co-development of oral insulin with Nobex (Research Triangle Park, NC, US), which it recently acquired. Strategic alliance with Karolinska Institute (Solna, Sweden) |
| Biological E | Collaboration on Hib conjugate vaccine with RIVM (Bilthoven, The Netherlands). Technology transfer agreements with two research institutes in China and collaboration with a Chinese company for hepatitis A vaccine, EPO and g-CSF. Agreement with Intercell (Vienna) to develop, manufacture and sell Intercell's Japanese encephalitis vaccine in Asia. Developing cholera vaccine with clone in-licensed from the International Centre for Diarrheal Disease Research (Dacca, Bangladesh) |
| Clinigene | Conducting two phase 3 studies for Merck in the US |
| Dr. Reddy's Laboratories | Co-development and commercialization of balaglitazone (for type 2 diabetes) with Rheoscience (Rødovre, Denmark). Development and marketing of 11 generic pharmaceuticals with Pharmascience Group of Canada. Past relationship with InCyte Genomics (Wilmington, DE, US) for data mining to discover targets for diabetes |
| Indian Immunologicals | Collaborative project for the production of human monoclonal antibodies with Thomas Jefferson Medical School (Philadelphia). Collaborated with Harvard Medical school (Boston) to develop polysaccharide vaccines. Past collaboration with the Wellcome Foundation (London) to build company's plant at Hyderabad. Marketing agreement for rabies vaccine with Pfizer (New York, New York, US) in South East Asia |
| Lifecare Innovations | Collaboration with the Council for Scientific and Industrial Research (Pretoria, South Africa) led-consortium for clinical development and commercialization of a sustained release PLG (poly DL-lactide-co-glycolide) anti-TB product |
| Nicholas Piramal India (NPIL) | Marketing biotechnology products for Hoffman-La Roche(Basel), Gilead Sciences (Foster City, CA US), Chiesi Farmaceutici (Parma, Italy) and Genzyme (Cambridge, MA US). NPIL to provide process development and scale-up/manufacturing services to Pfizer's animal health division and other major pharma companies. NPIL to manufacture and supply select hospital care products for a large global hospital products company. Licensed vaccine technology from Canada's National Research Council (Ottawa) |
| Panacea Biotec | Co-development of non-refrigerated vaccines with Cambridge Biostability (Cambridge, UK). Collaboration with a leading European multinational corporation on an anti-hypertensive drug candidate using Panacea's drug delivery technology. Technology transfer from the US National Institute of Health for development of a peptide for human hair growth |
| Serum Institute of India | Worked with Netherlands-based National Institute for Public Health and the Environment (RIVM) to develop its Hib vaccine |
| Shantha Biotechnics | Co-development of cholera and typhoid vaccines with International Vaccine Institute (Seoul). Shantha distributing Japanese encephalitis vaccine in India for GreenCross Vaccine (Yongin-Si, Korea). Distribution of Hep-B vaccine in US through Spectrum Pharmaceuticals (Irvine, CA, US) and meningitis vaccine in India through Baxter (Deerfield, IL, US). Shantha's 'Hepashield' was marketed through Pfizer in the past. Co-development of heat-stable vaccines with Cambridge Biostability. Technology transfer agreement with Polytherics (London) to develop a PEG-interferon product (for hepatitis C). Agreement with a large European company to co-develop pentavalent vaccines |
| SIRO Clinpharm | Conducts clinical development work for Pfizer and Covance (Princeton, NJ US) |
| Strand Life Sciences | Contract development of software with Affymetrix (Santa Clara, CA US) for their microarray analysis systems. Marketing relationship wtih CombiMatrix (Mukilteo, WA US) to market Strand's flagship software (Avadis) for microarray analysis. Partnership with MediBIC Alliance (Tokyo) to develop bioinformatics solutions for Japanese companies. Partnership with BioRad (Hercules, CA, US) for its predictive ADME unit. Co-development of bioinformatics software tools for Affymetrix arrays with Stratagene (La Jolla, CA, US). Collaborative research with Elan Pharmaceuticals (Dublin). Distribution of Acuris, a bioinformatics tool to automate gene and protein annotation, through UBI (Calgary, Canada) |
| Syngene | Work on bacterial virulence factors with Innate Pharmaceuticals (Umea, Sweden). Working on TB with a Singapore-based group. Doing some work for GlaxoSmithKline in the UK. |
| Transgene Biotek | Phase 3 clinical trials for quadrivalent meningococcal vaccine conducted in Africa through partnership with a US-based company. Co-development with a US-based company for cancer drugs based on siRNA |
| Wockhardt | Collaboration regarding Wockhardt's hospital business with Howard Hughes Medical Institute (Chevy Chase, MD, US). Manufacturing agreements with AstraZeneca's Cell Therapeutics (Seattle, WA US), Sanofi-Aventis (Paris), Aguettant (Lyon, France), Schering-Plough (Kenilworth, NJ US) and Eisai (Tokyo) |